Statement Of Cash Flows [Abstract]
| Concept |
2024-01-01 to 2024-12-31 |
2023-01-01 to 2023-12-31 |
|---|---|---|
| Statement of cash flows [abstract] | ||
| Cash flows from (used in) investing activities [abstract] | ||
| Purchase of biological assets |
48,000,000
EUR
|
48,000,000
EUR
|
| Proceeds from sales or maturity of financial instruments, classified as investing activities |
—
EUR
|
2,000,000
EUR
|
| Cash flows from (used in) financing activities [abstract] | ||
| Dividends paid to equity holders of parent, classified as financing activities |
1,081,000,000
EUR
|
345,000,000
EUR
|
| Dividends paid to non-controlling interests, classified as financing activities |
6,000,000
EUR
|
7,000,000
EUR
|
| Proceeds from non-current borrowings |
215,000,000
EUR
|
—
EUR
|
| Repayments of non-current borrowings |
215,000,000
EUR
|
—
EUR
|
| Proceeds from current borrowings |
9,000,000
EUR
|
16,000,000
EUR
|
| Repayments of current borrowings |
18,000,000
EUR
|
33,000,000
EUR
|
| Proceeds from issue of bonds, notes and debentures |
496,000,000
EUR
|
—
EUR
|
| Repayments of bonds, notes and debentures |
500,000,000
EUR
|
—
EUR
|
| Proceeds from contributions of non-controlling interests |
3,000,000
EUR
|
—
EUR
|